U.S. flag

An official website of the United States government

Display Settings:

Items per page

PMC Full-Text Search Results

Items: 6

1.
FIG 5.

FIG 5. From: Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas.

Genomic risk stratification and distribution of common mutation and comutation patterns by each risk group.

Ronglai Shen, et al. JCO Precis Oncol. 2019;3:PO.18.00307.
2.
FIG 6.

FIG 6. From: Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas.

(A) Risk score distribution from the OncoCast-TR (targeted therapies) model stratifies patients into two subsets. (B) Overall survival probability for the two TR patient subsets (TR1 and TR2). (C) Gene importance plot for the OncoCast-TR model.

Ronglai Shen, et al. JCO Precis Oncol. 2019;3:PO.18.00307.
3.
FIG 4.

FIG 4. From: Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas.

Overlaying OncoCast risk score with tumor mutation burden, mutational signature, smoking status, and mutation status for commonly mutated genes. APOBEC, apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like.

Ronglai Shen, et al. JCO Precis Oncol. 2019;3:PO.18.00307.
4.
FIG 1.

FIG 1. From: Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas.

Prognostic relevance and clonality of cancer genes. (A) Plot of selection frequency in each model and regression coefficients for individual genes; the black vertical bar shows favorable versus unfavorable association with overall survival. (B) Clonality analysis of the cancer gene alterations. Circle size is proportional to mutation frequency.

Ronglai Shen, et al. JCO Precis Oncol. 2019;3:PO.18.00307.
5.
FIG 3.

FIG 3. From: Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas.

Outcome prediction on the basis of risk score. (A) Kaplan-Meier plot of survival curves for the four risk subgroups (Low, intermediate-low [Int-low], intermediate-high [Int-high], and high). Colored areas represent 95% CIs. The average risk score (Avg RS), median overall survival (OS), and 1-year and 3-year survival probabilities are reported for each group. (B) Forest plot of hazard ratios (HRs) for age, sex, smoking status, and individual driver gene alterations compared with the OncoCast integrated scoring approach.

Ronglai Shen, et al. JCO Precis Oncol. 2019;3:PO.18.00307.
6.
FIG 2.

FIG 2. From: Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas.

An integrated prognostic scoring system for metastatic lung adenocarcinomas. (A) Histogram of the prognostic risk score computed using the OncoCast model in 1,054 metastatic lung adenocarcinomas. The risk score is scaled from 0 to 10, with a higher score indicating higher likelihood of shorter survival. Dashed lines indicate the percentile cutoffs used to stratify patients into four risk subgroups (low, intermediate-low, intermediate-high, and high). (B) Boxplots of concordance index for predicting overall survival using clinical demographic factors including age, sex, smoking, and the OncoCast risk score. CN, copy number; mut, mutation.

Ronglai Shen, et al. JCO Precis Oncol. 2019;3:PO.18.00307.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center